A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NAbs / Neutralizing antibodies

[Related PubMed/MEDLINE]
Total Number of Papers: 69
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NAbs  (>> Co-occurring Abbreviation)
Long Form:   Neutralizing antibodies
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule. ---
2018 An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. AAV, CTLs, hFVIII
2018 Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. bNAbs, Envs, HIV-1, mAbs
2018 Nab Escaping AAV Mutants Isolated from Mouse Muscles. AAV
2018 Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane. CHIKV, FcRs
2017 Amplification and selection of PRRSV-activated VDJ repertoires in pigs secreting distinct neutralizing antiboidies. CDRs, PRRSV
2017 MxA mRNA decrease preceding NAb detection in IFNbeta-treated MS patients. IFN-beta, MS, MxA
2017 Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine. DENV, LATVs, mAbs, N-MAbs, SHM
2016 Immunogenicity of Human Interferon-Beta-Containing Pharmaceuticals. IFN-beta
10  2016 Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk. IQR, MTCT
11  2016 Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics. ADAs, MOA
12  2015 An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus. FIV, HIV
13  2015 Biological monitoring of IFN-beta therapy in Multiple Sclerosis. MS, MxA
14  2015 Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Ig, PsV
15  2015 ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. AAE
16  2015 Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. HCV
17  2014 A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. APS1, AVA, CBAA, ELISA, IFN, RLBA
18  2014 Antibodies against interferon-beta in neuromyelitis optica patients. BAbs, NMO
19  2014 Broadly neutralizing antibodies abrogate established hepatitis C virus infection. HCV
20  2014 Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. HCV
21  2014 Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect alpha/beta interferon-receptor knock-out (IFNAR(-/-)) mice from homologous lethal challenge. BTV, GST
22  2014 Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. CRF, Env
23  2014 Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. ---
24  2014 Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. GMTs
25  2014 Smoking and risk of treatment-induced neutralizing antibodies to interferon beta-1a. CI, IFN-beta, MS, OR
26  2014 The effect of the TLR9 ligand CpG-oligodeoxynucleotide on the protective immune response to alcelaphine herpesvirus-1-mediated malignant catarrhal fever in cattle. AlHV-1, atAlHV-1, MCF, tAb
27  2013 Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. ---
28  2013 Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. AAVs, FIX
29  2013 Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). bNAbs, HIV-1
30  2012 Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach. ---
31  2012 Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. IFN-beta, PBMCs, RRMS
32  2012 MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. HHV-6, IFN-beta
33  2012 Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. IFN-beta, MS, NU
34  2012 Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. IFN-beta
35  2012 The Antibody Response against HIV-1. mAbs
36  2011 A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. HCV, VLPs
37  2011 Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. MS
38  2011 Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. ---
39  2011 Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. HIV-C, SHIV, SIV
40  2010 A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Ad.IFN-beta, MPE, MPM, PET, RECIST
41  2010 Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. IFNbeta-1b, LTF
42  2010 Immunogenicity of osteogenic protein 1: results from a prospective, randomized, controlled, multicenter pivotal study of uninstrumented lumbar posterolateral fusion. ELISA, OP-1
43  2010 Neutralization of feline immunodeficiency virus by antibodies targeting the V5 loop of Env. FIV
44  2009 Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. IFIT1, IFN-beta, MS, MxA, s.c, TRU
45  2009 High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. HINABS, IFN-beta, MxA
46  2009 Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. IFN, MS, MxA
47  2009 Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-beta. IFN-beta, MP, MxA, NC
48  2009 Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection. CPE, EFNS, EMCV, WHO
49  2009 Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. IFN-beta, MS
50  2009 Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b. OPTIMS
51  2009 Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. AAV2
52  2009 Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. DEX, rAds
53  2008 Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. CLDN1, HCV
54  2008 Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant. p.i, SIV
55  2008 Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. BAbs, CPE, EMCV, IFN-beta, MS
56  2007 Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? CPE, IFN, MS
57  2007 Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus. CTL, LCMV
58  2007 The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. MS
59  2006 A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients. IFN, MS
60  2006 Enhanced transduction of mouse salivary glands with AAV5-based vectors. rAAV2
61  2006 The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. IFN-beta, MRI, MS, RRMS
62  2005 Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. IFN, MS
63  2005 Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. IFNbeta-1a, MS, NAb
64  2005 Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. ACE2, SARS
65  2004 Immunogenicity of interferon beta: differences among products. IFN-beta
66  2004 Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. IFN-beta
67  2004 Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. GA, IFN-beta, MS
68  2004 Neutralizing antibodies to multiple sclerosis treatments. IFN-beta, IM, MS, s.c
69  2001 Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis. ---